ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies

American Society of Hematology. (2024).
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.

American Society of Hematology.
"ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies
(label-accessed October 31, 2025).

"American Society of Hematology."
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies, 31 Oct. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero